As of March 17, 0.25 milligram / 0.5 milligram, 2 milligram / 3 milliliters and 1 milligram solutions of Ozempic (semaglutide) injections are available. There is “limited availability” of the 2 milligram solution, and the 0.25 milligram / 0.5 milligram, 2 milligram / 1.5 milliliters injection product will be discontinued, according to the FDA.
In 2022, increased demand pushed Novo Nordisk’s diabetes drug Ozempic and weight loss drug Wegovy (semaglutide) into shortage. All Wegovy solutions are available, and the drugmaker told the American Society of Health-System Pharmacists “is working to resolve the [Ozempic supply] issue by early 2023,” according to a March 17 post.
Some diabetes patients have been rationing their Ozempic supply, and some pharmacies do not stock the drug because of low reimbursement rates from pharmacy benefit managers.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
